Target intelligence / Profile preview

Flavin adenine dinucleotide (FAD)

Target
FAD
Molecular classification
Other, Cofactor, Vitamin-derived metabolite
01

Overview

Flavin adenine dinucleotide (FAD) is a redox-active coenzyme derived from riboflavin (vitamin B2). It acts as a critical electron carrier in cellular metabolism, particularly within mitochondrial oxidative phosphorylation and the citric acid cycle, where it shuttles electrons between metabolic intermediates and the electron transport chain[1][3][4][6][7][10]. FAD is essential for the function of a broad array of flavoproteins and enzymes, including oxidoreductases, dehydrogenases, and monooxygenases, all of which mediate key oxidative and reductive biochemical reactions[4][6][7]. As a coenzyme, FAD is vital for energy production, amino acid metabolism, fatty acid oxidation, and DNA repair in living systems[1][3][4][6][7][10]. Human cells synthesize FAD from dietary riboflavin via the sequential activities of riboflavin kinase (producing FMN) and FAD synthase[1][5][6]. Disruption of FAD biosynthesis or riboflavin deficiency leads to impaired energy metabolism and can contribute to neurological, metabolic, or mitochondrial disorders[1][4]. Note: Flavin adenine dinucleotide is a metabolite/cofactor, not a conventional therapeutic target such as a receptor, enzyme, or transporter[1][4][10]. Thus, while it is essential for the function of many drug targets, it is not itself directly targeted by therapeutic drugs; instead, it is required for the proper activity of flavoprotein enzymes that are sometimes drug targets[3][4].

Other names
FADFlavin adenine dinucleotide (oxidized form)FADH2 (reduced form)Riboflavin-adenine dinucleotide
02

Biological functions

Redox reactionsElectron transportCellular respirationEnergy productionMetabolism of carbohydrates, amino acids, and fatty acidsDNA repairRegulation of apoptosisPhotoreception in some organisms
03

Disease associations

Other (deficiency impacts metabolism; indirectly relevant in mitochondrial diseases, some neurodegenerative and metabolic disorders due to its key role in energy production)
04

Safety considerations

null (FAD is an endogenous metabolite; safety concerns relate to deficiency or disruption of its biosynthesis, not direct targeting)
05

Biomarkers

Plasma/serum FAD levels (used as a biomarker for riboflavin status; not commonly used for patient selection in clinical therapeutics)

Beyond the preview

Go deeper on Flavin adenine dinucleotide (FAD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flavin adenine dinucleotide (FAD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call